PURPOSE: Injection of a hydrogel spacer before prostate cancer radiotherapy (RT) is known to reduce the dose to the rectal wall. Clinical results from the patient's perspective are needed to better assess a possible benefit. METHODS: A group of 167 consecutive patients who received prostate RT during the years 2010 to 2013 with 2‑Gy fractions up to 76 Gy (without hydrogel, n = 66) or 76-80 Gy (with hydrogel, n = 101) were included. The numbers of interventions resulting from bowel problems during the first 2 years after RT were compared. Patients were surveyed prospectively before RT, at the last day of RT, and at a median of 2 and 17 months after RT using a validated questionnaire (Expanded Prostate Cancer Index Composite). RESULTS: Baseline patient characteristics were well balanced. Treatment for bowel symptoms (0 vs. 11 %; p < 0.01) and endoscopic examinations (3 vs. 19 %; p < 0.01) were performed less frequently with a spacer. Mean bowel function scores did not change for patients with a spacer in contrast to patients without a spacer (mean decrease of 5 points) >1 year after RT in comparison to baseline, with 0 vs. 12 % reporting a new moderate/big problem with passing stools (p < 0.01). Statistically significant differences were found for the items "loose stools", "bloody stools", "painful bowel movements" and "frequency of bowel movements". CONCLUSION: Spacer injection is associated with a significant benefit for patients after prostate cancer RT.
PURPOSE: Injection of a hydrogel spacer before prostate cancer radiotherapy (RT) is known to reduce the dose to the rectal wall. Clinical results from the patient's perspective are needed to better assess a possible benefit. METHODS: A group of 167 consecutive patients who received prostate RT during the years 2010 to 2013 with 2‑Gy fractions up to 76 Gy (without hydrogel, n = 66) or 76-80 Gy (with hydrogel, n = 101) were included. The numbers of interventions resulting from bowel problems during the first 2 years after RT were compared. Patients were surveyed prospectively before RT, at the last day of RT, and at a median of 2 and 17 months after RT using a validated questionnaire (Expanded Prostate Cancer Index Composite). RESULTS: Baseline patient characteristics were well balanced. Treatment for bowel symptoms (0 vs. 11 %; p < 0.01) and endoscopic examinations (3 vs. 19 %; p < 0.01) were performed less frequently with a spacer. Mean bowel function scores did not change for patients with a spacer in contrast to patients without a spacer (mean decrease of 5 points) >1 year after RT in comparison to baseline, with 0 vs. 12 % reporting a new moderate/big problem with passing stools (p < 0.01). Statistically significant differences were found for the items "loose stools", "bloody stools", "painful bowel movements" and "frequency of bowel movements". CONCLUSION: Spacer injection is associated with a significant benefit for patients after prostate cancer RT.
Authors: Michael Pinkawa; Nuria Escobar Corral; Mariana Caffaro; Marc D Piroth; Richard Holy; Victoria Djukic; Gundula Otto; Felix Schoth; Michael J Eble Journal: Radiother Oncol Date: 2011-09-29 Impact factor: 6.280
Authors: B A Jereczek-Fossa; C Pobbiati; L Santoro; C Fodor; P Fanti; S Vigorito; G Baroni; D Zerini; O De Cobelli; R Orecchia Journal: Strahlenther Onkol Date: 2013-08-17 Impact factor: 3.621
Authors: Danny Y Song; Klaus K Herfarth; Matthias Uhl; Michael J Eble; Michael Pinkawa; Baukelien van Triest; Robin Kalisvaart; Damien C Weber; Raymond Miralbell; Theodore L Deweese; Eric C Ford Journal: Int J Radiat Oncol Biol Phys Date: 2013-02-13 Impact factor: 7.038
Authors: M Pinkawa; M D Piroth; R Holy; N Escobar-Corral; M Caffaro; V Djukic; J Klotz; M J Eble Journal: Strahlenther Onkol Date: 2012-08-31 Impact factor: 3.621
Authors: Neil Mariados; John Sylvester; Dhiren Shah; Lawrence Karsh; Richard Hudes; David Beyer; Steven Kurtzman; Jeffrey Bogart; R Alex Hsi; Michael Kos; Rodney Ellis; Mark Logsdon; Shawn Zimberg; Kevin Forsythe; Hong Zhang; Edward Soffen; Patrick Francke; Constantine Mantz; Peter Rossi; Theodore DeWeese; Daniel A Hamstra; Walter Bosch; Hiram Gay; Jeff Michalski Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-23 Impact factor: 7.038
Authors: Gencay Hatiboglu; Michael Pinkawa; Jean-Paul Vallée; Boris Hadaschik; Markus Hohenfellner Journal: BJU Int Date: 2012-07-12 Impact factor: 5.588
Authors: Michael Pinkawa; Marc D Piroth; Richard Holy; Victoria Djukic; Jens Klotz; Barbara Krenkel; Michael J Eble Journal: Strahlenther Onkol Date: 2011-07-25 Impact factor: 3.621
Authors: Thierry M Muanza; Paul S Albert; Sharon Smith; Denise Godette; Nancy Sears Crouse; Theresa Cooley-Zgela; Linda Sciuto; Kevin Camphausen; C Norman Coleman; Cynthia Ménard Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-01 Impact factor: 7.038
Authors: Avani D Rao; Ziwei Feng; Eun Ji Shin; Jin He; Kevin M Waters; Stephanie Coquia; Robert DeJong; Lauren M Rosati; Lin Su; Dengwang Li; Juan Jackson; Stephen Clark; Jeffrey Schultz; Danielle Hutchings; Seong-Hun Kim; Ralph H Hruban; Theodore L DeWeese; John Wong; Amol Narang; Joseph M Herman; Kai Ding Journal: Int J Radiat Oncol Biol Phys Date: 2017-08-14 Impact factor: 7.038
Authors: Ziwei Feng; Avani D Rao; Zhi Cheng; Eun Ji Shin; Joseph Moore; Lin Su; Seong-Hun Kim; John Wong; Amol Narang; Joseph M Herman; Todd McNutt; Dengwang Li; Kai Ding Journal: Int J Radiat Oncol Biol Phys Date: 2018-07-19 Impact factor: 7.038
Authors: Ben G L Vanneste; Y van Wijk; L C Lutgens; E J Van Limbergen; E N van Lin; K van de Beek; P Lambin; A L Hoffmann Journal: Strahlenther Onkol Date: 2017-10-16 Impact factor: 3.621
Authors: Peter Hass; Ingo G Steffen; Maciej Powerski; Konrad Mohnike; Max Seidensticker; Frank Meyer; Thomas Brunner; Robert Damm; Christoph Willich; Mathias Walke; Efstratios Karagiannis; Jazan Omari; Jens Ricke Journal: J Contemp Brachytherapy Date: 2019-04-29